Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer. It is a humanized...
3 KB (116 words) - 00:11, 1 January 2024
Monomethyl auristatin F (redirect from Mafodotin)
drug belantamab mafodotin in multiple myeloma and some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A....
4 KB (248 words) - 20:11, 4 October 2021
November: initiation of Phase I clinical trial for SGN-75 (INN: vorsetuzumab mafodotin) 11 December: termination of collaboration with Genentech for SGN-40...
37 KB (3,269 words) - 10:41, 19 June 2024
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
8 KB (316 words) - 22:44, 25 April 2024
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
52 KB (6,302 words) - 07:19, 27 April 2024
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
8 KB (501 words) - 01:30, 27 December 2023
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
12 KB (1,356 words) - 18:10, 27 December 2023
humanized CD134 cancer Vopratelimab mab humanized CD278, aka ICOS Vorsetuzumab mafodotin mab humanized CD70 cancer Votumumab HumaSPECT mab human tumor antigen...
135 KB (4,054 words) - 22:35, 2 July 2024
but a 1999 study found CD70 on 71% of large B-cell lymphomas. Vorsetuzumab mafodotin (antibody conjugated to monomethyl auristatin F). Monomethyl auristatin...
20 KB (2,453 words) - 10:36, 1 June 2024
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
19 KB (2,200 words) - 05:21, 25 December 2023
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
24 KB (2,853 words) - 21:22, 2 April 2024
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
12 KB (1,508 words) - 17:56, 19 August 2022
Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin† Duvortuxizumab Ontuxizumab§...
5 KB (368 words) - 22:00, 19 October 2020
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
12 KB (1,459 words) - 03:14, 30 October 2022
Teneliximab Tigatuzumab Toralizumab Urelumab Utomilumab Varlilumab Vorsetuzumab Vorsetuzumab mafodotin Decoy receptors: Briobacept Other inhibitors: Blisibimod...
12 KB (1,494 words) - 10:51, 13 August 2023
Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin† Duvortuxizumab Ontuxizumab§...
3 KB (129 words) - 01:04, 19 July 2023
January 2014 a safety and efficacy phase of the study started. Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical...
10 KB (1,089 words) - 22:01, 21 December 2023
Vanucizumab§ Veltuzumab§ Vorsetuzumab mafodotin§ Rat/mouse hybrid Catumaxomab Ertumaxomab§ Chimeric + humanized Depatuxizumab mafodotin† Duvortuxizumab Ontuxizumab§...
4 KB (241 words) - 11:41, 22 April 2022